Вступ
Innovent Biologics is an investment holding company primarily engaged in the research, development, production, and marketing of innovative drugs for the treatment of major diseases such as oncology, cardiovascular and metabolic diseases (CVM), autoimmune diseases, and ophthalmological diseases. Drug formulations include monoclonal antibodies, multispecific antibodies, immune cytokines, antibody-drug conjugates (ADCs), cell therapy, and small molecule drugs. The company's main products include Tyvyt (sintilimab injection), Davogene (bevacizumab injection), Sulixin (adalimumab injection), Dabohua (rituximab injection), and Dabertan (pemitinib tablets). The company primarily operates in the Chinese domestic and overseas markets.
